Clinical trials
Lung Cancer (NSCLC) clinical trials
Below are recruiting lung cancer (nsclc) clinical trials, each written for real people, not researchers. We’re tracking 1,096 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05060796RecruitingEarly Phase 1
CAR-T treatment for advanced lung cancer with EGFR and CXCL13 signs
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
GuangzhouAges 18–75 - NCT05669846RecruitingPhase 2
FMT plus pembrolizumab for advanced lung cancer after prior treatment
This Phase 2 trial studies whether adding fecal microbiome transplant (FMT) to pembrolizumab can help people with advanced, PD-L1–positive non-small cell lung cancer that has returned or progressed after anti–PD-1/PD-L1 therapy. You may be asked to give new tumor tissue and undergo gut procedures, because the study aims to change gut bacteria to boost the immune response.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06195527Recruiting
Pembrolizumab blood level monitoring for NSCLC
This study checks how well pembrolizumab (Keytruda) works in people with non-small cell lung cancer (NSCLC) by measuring the drug levels in your blood. It aims to see if adjusting the dose based on these levels improves treatment and reduces side effects.
AngersAges 18 years+ - NCT06364917RecruitingPhase 2
Comparing two immunotherapy options for PD-L1 negative lung cancer
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Birmingham, AlabamaAges 18–89 - NCT06424899RecruitingPhase 2
Chemoimmunotherapy before and after chemoradiation for stage III lung cancer
This study tests whether combining chemotherapy with immunotherapy before and after chemoradiation helps people with stage III lung cancer that can be removed by surgery. It might improve how well treatment works and reduce the chance of cancer coming back.
Hangzhou, ZhejiangAges 18–75 - NCT06467617RecruitingPhase 2
Immunotherapy and chemo before and after lung cancer surgery
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06563999RecruitingPhase 2
Study of new drugs for stage III lung cancer with rare gene changes
This trial tests whether giving treatment before surgery (neoadjuvant therapy) can help people with stage III lung cancer that has certain rare gene changes. The goal is to see if this approach can shrink the tumor enough to allow surgery.
Guangzhou, GuangdongAges 18–75 - NCT06598839Recruiting
Immune effects of thymosin alpha-1 for stage I lung cancer
This trial tests whether thymosin alpha-1, an immune-boosting medicine, can help people with stage I non-small cell lung cancer after surgery. The goal is to see if it improves the immune system's response and recovery.
Beijing, Beijing MunicipalityAges 18–75 - NCT06926413RecruitingPhase 1
How aumolertinib changes midazolam levels in lung cancer patients
This study tests how a lung cancer pill called aumolertinib affects the levels of another drug (midazolam) in your body. It is for people with advanced NSCLC whose tumors have specific EGFR gene changes.
Hangzhou, ZhejiangAges 18 years+ - NCT07193641RecruitingPhase 2
Lattice radiotherapy with standard care for slow-growing lung cancer
This trial tests whether adding a special radiotherapy technique called lattice radiotherapy to your usual cancer treatment can help control NSCLC that has started to grow in a few new spots. If you have up to 5 growing tumors and at least one measures 4.5 cm or larger, this study might be an option.
Hangzhou, ZhejiangAges 18 years+ - NCT07269782RecruitingPhase 2
Pre-surgery treatment for stage II-III lung cancer
This study tests two investigational drugs (HLX43 and serplulimab) given before surgery to people with stage II to III non-small cell lung cancer (NSCLC). The goal is to see if these drugs can shrink the tumor and make it easier to remove completely during surgery.
ShanghaiAges 18–75 - NCT03193567RecruitingPhase 1
Cell therapy study for advanced lung cancer after treatment failure
This Phase 1 trial tests a powerful “killing cell” therapy for people with advanced non-small cell lung cancer whose cancer did not respond to standard chemotherapy and targeted drugs. The goal is to see if this new treatment is safe and may work after other treatments have failed.
ShanghaiAges 18–70 - NCT05692999RecruitingPhase 3
Maintenance pembrolizumab dose study for non-squamous lung cancer
This Phase 3 trial tests two maintenance schedules (“usual” dose versus a lower dose) of pembrolizumab after your initial chemotherapy with pembrolizumab. It aims to see if the lower dose works well enough to control cancer while possibly reducing side effects.
NamurAges 18 years+ - NCT06041776RecruitingPhase 3
Befotertinib after surgery for early-stage lung cancer with EGFR mutation
This trial tests if a targeted therapy pill (befotertinib) can lower the chance of cancer coming back after surgery for non-small cell lung cancer that has a specific EGFR mutation. You may be eligible if your tumor was completely removed and you have stage IB to IIIB disease.
BeijingAges 18 years+ - NCT06934343Recruiting
Personalized therapy for advanced lung cancer using data
This trial uses real-world data to study how to personalize treatment for advanced non-small cell lung cancer. It looks at medical records from 2011 to 2024 to find the best therapy approaches.
Salt Lake City, UtahAges Any age - NCT05076760RecruitingPhase 1
Study of a cancer-killing virus with standard treatments
This Phase 1 trial tests MEM-288, an oncolytic (cancer-killing) virus, either alone or combined with standard cancer medicines, in people with advanced solid tumors. It’s designed to see how the treatment works and how safe it is in different cancer types and after specific prior therapies.
Tampa, FloridaAges 18 years+ - NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Beverly Hills, CaliforniaAges 18 years+ - NCT04105270RecruitingPhase 2
Durvalumab plus chemo with RMT for lung cancer
This Phase 2 trial studies a new treatment plan that combines RMT with durvalumab and chemotherapy in people with untreated advanced lung adenocarcinoma. It aims to improve outcomes by helping the immune system and fighting cancer cells together.
Phoenix, ArizonaAges 18 years+ - NCT04916990Recruiting
Care program for rural adults with several lung and head cancers
This study looks at how to improve care for adults with certain cancers who live in rural areas and may face access problems. It mainly focuses on people receiving cancer treatment at specific Colorado-area hospitals, and who are uninsured or underinsured.
Aurora, ColoradoAges 18–99 - NCT07063745RecruitingPhase 2/Phase 3
Comparing a new drug combo for advanced lung cancer with a specific gene change
This trial tests a new drug called Navlimetostat combined with pembrolizumab and chemotherapy versus a placebo with the same standard treatments. It is for people with metastatic non-small cell lung cancer that has a specific missing gene (MTAP deletion) and who have not had prior treatment for their advanced disease.
Anchorage, AlaskaAges 18 years+ - NCT05504278RecruitingPhase 1
Testing IBI351 with chemotherapy for KRAS G12C lung cancer
This Phase 1 study tests whether IBI351, a targeted medicine, can be safely given with standard chemotherapy to treat advanced lung cancer that has a KRAS G12C mutation. It’s mainly looking at safety and early signs of effectiveness, and may offer a new option if your cancer matches these features.
Jilin City, ChangchunAges 18–75 - NCT04335292RecruitingPhase 2
Osimertinib then chemotherapy for EGFR-mutated lung cancer
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Vancouver, British ColumbiaAges 18 years+ - NCT04806412Recruiting
Gene testing in lung cancer fluid samples
This study looks at fluid from around the lungs (pleural fluid) to find gene changes (oncodrivers) in people with non-small cell lung cancer. The goal is to see if this fluid can replace a tissue biopsy for testing.
Næstved, Region SjællandAges 18 years+ - NCT05922345RecruitingPhase 3
Study drug vs docetaxel for advanced lung cancer after prior treatment
This Phase 3 trial compares AL2846 pills plus TQB2450 injections against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer. You may qualify if your cancer has progressed after platinum chemotherapy and immunotherapy, and if certain tumor genetic tests are negative.
Hefei, AnhuiAges 18–75
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (nsclc)?
- Yes. Clin2 currently lists 1,096 recruiting lung cancer (nsclc) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (nsclc) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (nsclc) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.